Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy Nanotech Investing
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines Nanotech Investing
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET Nanotech Investing
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress Nanotech Investing
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 Nanotech Investing
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Nanotech Investing
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares Nanotech Investing
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial for Safusidenib in IDH1-Mutant Glioma Nanotech Investing
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation Nanotech Investing
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States Nanotech Investing
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq Nanotech Investing
